Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.35 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.35 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.35 |
| ▸ | CDK1 | P06493 | 2/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.35 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.35 |
| ▸ | SRC | P12931 | 2/20 | 0.35 |
| ▸ | BTK | Q06187 | 2/20 | 0.35 |
| ▸ | AHR | P35869 | 3/20 | 0.34 |
| ▸ | CMA1 | P23946 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 4/20 | 0.33 |
| ▸ | GSK3A | P49840 | 3/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.33 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1531608 | 0.83 | AKT1 (0.37) | TNNI3K | |
| SCHEMBL12382071 | 0.77 | SRC (0.46) | TNNI3KCDK5CDK5R1CCNB2CDK1 | |
| SCHEMBL14905180 | 0.77 | CDK5 (0.43) | TNNI3KCDK5CDK5R1CCNB2CDK1 | |
| SCHEMBL3527412 | 0.73 | AHR (0.38) | AHRCMA1 | |
| SCHEMBL580431 | 0.73 | CDK5 (0.47) | CDK5CDK5R1CCNB2CDK1CCNB1 | |
| SCHEMBL12590745 | 0.73 | TNNI3K (0.36) | TNNI3KCDK5CDK5R1SRCBTK | |
| SCHEMBL12833310 | 0.73 | TNNI3K (0.53) | TNNI3KCDK5SRCBTKGSK3B | |
| SCHEMBL18549312 | 0.73 | TNNI3K (0.39) | TNNI3KCDK5CDK5R1CCNB2CDK1 | |
| SCHEMBL18237428 | 0.73 | TNNI3K (0.39) | TNNI3KCDK5SRCBTKGSK3B | |
| SCHEMBL6479921 | 0.72 | AHR (0.44) | CDK5CDK5R1CCNB2CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 224 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111423445-A | Synthetic method of 4-chloro-5, 7-dihydro-6H-pyrrolo [2, 3-D ] pyrimidine-6-ketone | 安徽赛迪生物科技有限公司 | 2020-07-17 | — | — | CN | claimed |
| EP-4747258-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Tenvie Therapeutics, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| WO-2025024329-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | NICO THERAPEUTICS, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| CN-118359638-A | Compound serving as RET kinase inhibitor and preparation method and application thereof | 苏州朗睿生物医药有限公司 | 2024-07-19 | — | — | CN | disclosed |
| US-20230257352-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-08-17 | — | — | US | disclosed |
| US-20230257352-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-08-17 | — | — | US | disclosed |
| CN-112047932-B | Pyrazole spleen tyrosine kinase inhibitor and preparation method and application thereof | 中国药科大学 | 2022-11-08 | — | — | CN | disclosed |
| US-20210008055-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2021-01-14 | — | — | US | disclosed |
| CN-112047932-A | Pyrazole spleen tyrosine kinase inhibitor and preparation method and application thereof | 中国药科大学 | 2020-12-08 | — | — | CN | disclosed |
| US-20200247812-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | INTEGRAL BIOSCIENCES PRIVATE LTD (IN) | 2020-08-06 | — | — | US | disclosed |
| US-7138402-B2 | Pyrrolopyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2006-11-21 | — | — | US | disclosed |
| EP-1670802-A2 | NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS | Conforma Therapeutic Corporation (US) | 2006-06-21 | — | — | EP | disclosed |
| EP-1244672-B1 | 4-SUBSTITUTED 7-AZA-INDOLIN-2-ONES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUGEN INC (US) | 2005-07-20 | — | — | EP | disclosed |
| US-6908930-B2 | 4-substituted 7-AZA-indolin-2-ones and their use as protein kinase inhibitors | SUGEN, INC. (US) | 2005-06-21 | — | — | US | disclosed |
| US-20050130954-A1 | Serine/threonine protein kinase inhibitors; hyperproliferative disorder or inflammatory conditions; e.g. 4-(4-(2-amino-3-(p-chlorophenyl)-propionyl)-piperazin-1-yl)-quinazoline | ARRAY BIOPHARMA INC. | 2005-06-16 | — | — | US | disclosed |
| US-20050107343-A1 | Pyrrolopyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION | 2005-05-19 | — | — | US | disclosed |
| WO-2005028434-A2 | NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS | CONFORMA THERAPEUTICS CORPORATION (US) | 2005-03-31 | — | — | WO | disclosed |
| US-20040053924-A1 | 4-Substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors | SUGEN, INC. | 2004-03-18 | — | — | US | disclosed |
| US-6610688-B2 | For therapy of blood vessel proliferative disorders; fibrotic disorders; mesangial cell proliferative disorders; metabolic disorders; allergies; asthma; thrombosis; nervous system diseases; and cancer | SUGEN, INC. | 2003-08-26 | — | — | US | disclosed |
| US-20020183319-A1 | 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors | SUGEN, INC. | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107343-A1 | Pyrrolopyrimidines and related analogs as HSP90-inhibitors | HSP90AB2P, HSP90AB1, HSP90AA1 | TNNI3K 1307/4885CDK5 241/4885CDK5R1 385/4885 |
| US-20040053924-A1 | 4-Substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors | CDKN1A, CSNK1A1, CDK2 | TNNI3K 141/4885CDK5 29/4885CDK5R1 70/4885 |
| US-20020183319-A1 | 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors | CDKN1A, CDK7, CDK2 | TNNI3K 242/4885CDK5 20/4885CDK5R1 18/4885 |
| US-20210008055-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, CNR2 | TNNI3K 2439/4885CDK5 815/4885CDK5R1 382/4885 |
| US-20230257352-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | TNNI3K 69/4885CDK5 476/4885CDK5R1 734/4885 |
| US-20200247812-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | ACVR1, ACVRL1, ALK | TNNI3K 470/4885CDK5 52/4885CDK5R1 78/4885 |
| US-20050130954-A1 | Serine/threonine protein kinase inhibitors; hyperproliferative disorder or inflammatory conditions; e.g. 4-(4-(2-amino-3-(p-chlorophenyl)-propionyl)-piperazin-1-yl)-quinazoline | MTOR, CDK2, CLK2 | TNNI3K 180/4885CDK5 115/4885CDK5R1 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.